Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects

Journal of the American Heart Association

Volumn 7, Issue 4, 2018, Pages

  Wilcox, Christopher S ^a   Shen, Wen ^a   Boulton, David W ^b   Leslie, Bruce R ^c   Griffen, Steven C ^c,d  

^a GEORGETOWN UNIVERSITY   (United States)

^b ASTRAZENECA   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

^d JDRF   (United States)

Author keywords

Congestive heart failure; Diabetes mellitus; Potassium; Sodium; Urate

Indexed keywords

BUMETANIDE; DAPAGLIFLOZIN; GLUCOSE; MAGNESIUM; POTASSIUM; SODIUM; SODIUM PHOSPHATE COTRANSPORTER 2; URATE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; LOOP DIURETIC AGENT; URIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEMALE; GLUCOSURIA; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERURICEMIA; MALE; MAXIMUM CONCENTRATION; MINIMUM CONCENTRATION; NATRIURESIS; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM EXCRETION; TIME TO MAXIMUM PLASMA CONCENTRATION; URIC ACID BLOOD LEVEL; URINARY EXCRETION; ADMINISTRATION AND DOSAGE; ADOLESCENT; ADVERSE EVENT; BLOOD; DRUG INTERACTION; MIDDLE AGED; PHARMACOKINETICS; RISK ASSESSMENT; SODIUM INTAKE; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; BENZHYDRYL COMPOUNDS; BUMETANIDE; DRUG INTERACTIONS; FEMALE; GLUCOSIDES; HEALTHY VOLUNTEERS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; NATRIURESIS; RENAL ELIMINATION; RISK ASSESSMENT; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM, DIETARY; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; URIC ACID; YOUNG ADULT;

EID: 85042152654     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.117.007046     Document Type: Article

References (43)

1. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN. Discovery of dapagliflozin: a potent, selective renal sodiumdependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51:1145-1149
2. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38:405-414
3. Peene B, Benhalima K. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes. Ther Adv Endocrinol Metab. 2014;5:124-136
4. Ghezzi C, Yu AS, Hirayama BA, Kepe V, Liu J, Scafoglio C, Powell DR, Huang SC, Satyamurthy N, Barrio JR, Wright EM. Dapagliflozin binds specifically to sodium-glucose cotransporter 2 in the proximal renal tubule. J Am Soc Nephrol. 2017;28:802-810
5. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302:R75-R83
6. Brater DC. Clinical pharmacology of loop diuretics. Drugs. 1991;41:14-22
7. Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017;19:43-53
8. Yamamoto K. Pharmacological treatment of heart failure with preserved ejection fraction. Yonago Acta Med. 2017;60:71-76
9. Hardin EA, Grodin JL. Diuretic strategies in acute decompensated heart failure. Curr Heart Fail Rep. 2017;14:127-133
10. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128
11. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose cotransporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33-59
12. Hoorn EJ, Wilcox CS, Ellison DH. Diuretics. In: Brenner BM, Rector FC, eds. Brenner & Rector's the Kidney. 10th ed. Philadelphia, PA: Elsevier; 2016:1702-1733
13. Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989;36:682-689
14. Wilcox CS, Mitch WE, Kelly RA, Skorecki K, Meyer TW, Friedman PA, Souney PF. Response of the kidney to furosemide, I: effects of salt intake and renal compensation. J Lab Clin Med. 1983;102:450-458
15. Androne AS, Hryniewicz K, Hudaihed A, Mancini D, Lamanca J, Katz SD. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol. 2004;93:1254-1259
16. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805
17. Trullas JC, Morales-Rull JL, Casado J, Freitas Ramirez A, Manzano L, Formiga F. Rationale and design of the "Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial": a double-blind, randomized, placebo-controlled study to determine the effect of combined diuretic therapy (loop diuretics with thiazidetype diuretics) among patients with decompensated heart failure. J Card Fail. 2016;22:529-536
18. Wilcox CS, Guzman NJ, Mitch WE, Kelly RA, Maroni BJ, Souney PF, Rayment CM, Braun L, Colucci R, Loon NR. Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int. 1987;31:135-141
19. Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume-independent component to post-diuretic sodium retention in man. J Am Soc Nephrol. 1993;3:1878-1883
20. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93:397-404
21. Rahman A, Kittikulsuth W, Fujisawa Y, Sufiun A, Rafiq K, Hitomi H, Nakano D, Sohara E, Uchida S, Nishiyama A. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens. 2016;34:893-906
22. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657
23. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330-339
24. Brater DC, Pressley RH, Anderson SA. Mechanisms of the synergistic combination of metolazone and bumetanide. J Pharmacol Exp Ther. 1985;233:70-74
25. Wilcox CS, Loon NR, Ameer B, Limacher MC. Renal and hemodynamic responses to bumetanide in hypertension: effects of nitrendipine. Kidney Int. 1989;36:719-725
26. Ly JP, Onay T, Sison K, Sivaskandarajah G, Sabbisetti V, Li L, Bonventre JV, Flenniken A, Paragas N, Barasch JM, Adamson SL, Osborne L, Rossant J, Schnermann J, Quaggin SE. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol. 2011;22:113-123
27. Brater DC, Kaojaren S, Chennavasin P. Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects. J Pharmacol Exp Ther. 1983;227:92-97
28. Wilcox CS, Baylis C, Wingo CS. Glomerular-tubular balance and proximal regulation. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 2nd ed. New York, NY: Raven Press; 1992:1807-1841
29. Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, Ahn YB, Kim ES, Moon SD, Kim MJ, Ko SH. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11:e0165703
30. Zheng H, Liu X, Sharma NM, Li Y, Pliquett RU, Patel KP. Urinary proteolytic activation of renal epithelial Na+ channels in chronic heart failure. Hypertension. 2016;67:197-205
31. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjostrom CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016;18:590-597
32. Wen D, Cornelius RJ, Sansom SC. Interacting influence of diuretics and diet on BK channel-regulated K homeostasis. Curr Opin Pharmacol. 2014;15:28-32
33. Wilcox CS, Mitch WE, Kelly RA, Friedman PA, Souney PF, Rayment CM, Meyer TW, Skorecki KL. Factors affecting potassium balance during frusemide administration. Clin Sci. 1984;67:195-203
34. Mitch WE, Wilcox CS. Disorders of body fluids, sodium and potassium in chronic renal failure. Am J Med. 1982;72:536-550
35. Lytvyn Y, Skrtic M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuriamediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308:F77-F83
36. Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med. 2013;125:181-189
37. Lipkowitz MS. Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012;14:179-188
38. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol. 2008;155:1066-1075
39. El-Sheikh AA, van den Heuvel JJ, Krieger E, Russel FG, Koenderink JB. Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). Mol Pharmacol. 2008;74:964-971
40. Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG. Galectin 9 is the sugarregulated urate transporter/channel UAT. Glycoconj J. 2004;19:491-498
41. Cheeseman C. Solute carrier family 2, member 9 and uric acid homeostasis. Curr Opin Nephrol Hypertens. 2009;18:428-432
42. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513-519
43. Imai T, Akimoto T, Ito C, Masuda T, Nagata D. Management of diabetes associated with nephrotic syndrome: therapeutic potential of dapagliflozin for protracted volume retention. Drug Target Insights. 2015;9:29-31